A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2013
11/14/2013	US20130303515 Novel compounds useful for the treatment of metabolic and inflammatory diseases
11/14/2013	US20130303511 Nampt inhibitors
11/14/2013	US20130303508 Nampt inhibitors
11/14/2013	US20130303506 Amino-derivatives as novel inhibitors of histone deacetylase
11/14/2013	US20130303498 Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid
11/14/2013	US20130303497 Deuterated 5-ht1a receptor agonists
11/14/2013	US20130303495 Emulsion formulations
11/14/2013	US20130303494 Pharmaceutical Formulation Containing Gelling Agent
11/14/2013	US20130303493 Triazole Compounds that Modulate HSP90 Activity
11/14/2013	US20130303492 3,5-diaminopyrazole kinase inhibitors
11/14/2013	US20130303489 Multikinase inhibitors for use in the treatment of cancer
11/14/2013	US20130303484 Prodrugs of Modulators of ABC Transporters
11/14/2013	US20130303479 Antiretroviral Cyclonucleoside Compositions and Methods and Articles of Title of Invention Manufacture Therewith
11/14/2013	US20130303471 Novel pyrazole compounds
11/14/2013	US20130303468 Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent
11/14/2013	US20130303467 Crystal structures of sglt2 inhibitors and processes for preparing same
11/14/2013	US20130303462 Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
11/14/2013	US20130303446 Pharmaceutical combinations for the treatment of metabolic disorders
11/14/2013	US20130303443 Novel compounds and their effects on feeding behaviour
11/14/2013	US20130303439 Chimeric peptides including a penetrating peptide and a binding domain of pp2a catalytic subunit to caspase-9
11/14/2013	US20130303437 Antimicrobial therapy for bacterial infections
11/14/2013	US20130303436 Peptide therapeutics and methods for using same
11/14/2013	US20130302889 Differentiation of Bone Marrow Cells into Neuronal Cells and Uses Therefor
11/14/2013	US20130302442 Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
11/14/2013	US20130302441 Methods for the treatment of skin neoplasms
11/14/2013	US20130302417 Methods of treatment using a gastric retained gabapentin dosage form
11/14/2013	US20130302416 Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
11/14/2013	US20130302412 Transfer Factor Compositions
11/14/2013	US20130302409 Methods and compositions for cancer immunotherapy
11/14/2013	US20130302407 Bi-Functional Short-Hairpin RNA (Bi-shRNA) Specific for Single-Nucleotide KRAS Mutations
11/14/2013	US20130302399 Anti-pcsk9 antibodies and use thereof
11/14/2013	US20130302378 Matrix metalloproteinase inhibitors
11/14/2013	US20130302370 Reduction of concomitant infections in pigs by the use of pcv2 antigen
11/14/2013	US20130302359 Cytotoxic benzodiazepine derivatives
11/14/2013	US20130302357 Novel benzodiazepine derivatives
11/14/2013	US20130302356 Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent
11/14/2013	US20130302349 Novel ha binding agents
11/14/2013	US20130302339 Compositions for diagnosis and therapy of diseases associated with aberrant expression of kremen and or wnt
11/14/2013	US20130302332 Method for treating inflammation
11/14/2013	US20130302327 Marker for determination of sensitivity to triplet combination anti-cancer agent
11/14/2013	US20130302323 Methods for treating diffuse large b-cell lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents
11/14/2013	US20130302322 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
11/14/2013	US20130302319 Zeaxanthin for tumor treatment
11/14/2013	US20130302313 Hexon tat-ptd modified adenovirus and uses thereof
11/14/2013	US20130302305 Methods for Treating Gout in Patients Subpopulations
11/14/2013	US20130302303 Protein kinase inhibitors
11/14/2013	US20130302297 Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections
11/14/2013	US20130302290 Methods for treating a kidney injury
11/14/2013	US20130302284 Modulating oncolytic vsv and upregulating rae1 and nup98 with statins
11/14/2013	US20130302282 Inhibitors of Hepatitis C Virus
11/14/2013	US20130302280 Inhibitors of flaviviridae viruses
11/14/2013	US20130302278 Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
11/14/2013	US20130302274 Combination therapy
11/14/2013	US20130302264 Indole alkaloid compounds as melanogenesis promoters and uses thereof
11/14/2013	US20130302254 Antivenom
11/14/2013	US20130302249 Intestinal peptide targeting ligands
11/14/2013	DE102012009570A1 Komposition für nasale Anwendung Composition for nasal application
11/13/2013	EP2662453A2 Detection and treatment of schizophrenia
11/13/2013	EP2662092A1 Method for selecting patient to be given drug for treating septicemia
11/13/2013	EP2661274A1 Compositions and methods of aloe polysaccharides
11/13/2013	EP2661273A2 Pharmaceutical compositions of iron for oral administration
11/13/2013	EP2661269A1 Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
11/13/2013	EP2661175A1 Combination steroid and glucocorticoid receptor antagonist therapy
11/13/2013	CN1750839B Administration of capsaicinoids
11/13/2013	CN103391782A Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability
11/13/2013	CN103391780A Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
11/13/2013	CN103391779A Prostate cancer therapy with HSP90 inhibitory compounds
11/13/2013	CN103391774A Pharmaceutical composition comprising trans-cinnamaldehyde and its use in the treatment of infections
11/13/2013	CN103391773A Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
11/13/2013	CN103387955A Making method and use of non-human mammal B lymphocyte defect animal model
11/13/2013	CN103387601A Anti-dengue virus (DENV) heterocyclic peptide compounds and preparing methods and uses thereof
11/13/2013	CN103386131A Pharmaceutical composition containing adenosine or derivative of adenosine
11/13/2013	CN103386130A ACE inhibitor/thiazide diuretic/5-methyltetrahydrofolate pharmaceutical composition and applications
11/13/2013	CN103386119A Application of SIRT1 in adjusting rhythm and improving rhythm disorder
11/13/2013	CN102065897B New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
11/12/2013	US8580944 Suppressors of CpG oligonucleotides and methods of use
11/12/2013	US8580857 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
11/12/2013	US8580773 Small-molecule inhibitors of the androgen receptor
11/12/2013	US8580553 Phage-associated lytic enzymes for treatment of Bacillus anthracis and related conditions
11/12/2013	US8580303 Gastric retained gabapentin dosage form
11/12/2013	US8580302 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
11/12/2013	US8580280 Adjuvant compositions
11/12/2013	US8580246 Surfactant-free stable pharmaceutical composition comprising granulocyte-colony stimulating factor
11/12/2013	CA2714357C Mutations in neuronal gene sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
11/12/2013	CA2632780C Combination of r,r-glycopyrrolate, rolipram, and budesonide for the treatment of inflammatory diseases
11/12/2013	CA2576156C Use of xenon as neuroprotectant in a neonatal subject
11/12/2013	CA2557999C Methods and compositions for treatment of ion imbalances
11/12/2013	CA2537093C Compound capable of binding s1p receptor and pharmaceutical use thereof
11/07/2013	WO2013166318A1 Combination therapy for treating bladder cancer
11/07/2013	WO2003033664A9 Bone anti-resorptive compounds
11/07/2013	US20130296829 Non-sedating antihistamine injection formulations and methods of use thereof
11/07/2013	US20130296443 System and method of trans-venous pre-aortic ganglion ablation
11/07/2013	US20130296442 Lutein/zeaxanthin for glare protection
11/07/2013	US20130296434 Formulations and methods for treating amyloidosis
11/07/2013	US20130296430 Compositions and methods for treating autism and autism spectrum disorder
11/07/2013	US20130296416 Selective inhibition of beta1- adrenergic receptors for the treatment of pediatric heart failure
11/07/2013	US20130296411 Use of Artemisinin for Treating Tumors Induced by oncogenic Viruses and for Treating Viral Infections
11/07/2013	US20130296404 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same
11/07/2013	US20130296403 Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
11/07/2013	US20130296399 microRNA Biomarkers for Human Breast and Lung Cancer

1 ... 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 ... 1151